BOBostock Chinecherem Okafor

Bostock Chinecherem Okafor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bostock Chinecherem Okafor has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dose and time-dependent effect of orange juice on the antimalarial efficacy of artemether-lumefantrine, haematological, and antioxidant parameters

    by John K. Iregbu, Jessica C. Iregbu, Gabriel C. Edeh, Daniel L. Ajaghaku, Christian C. Nwoye, Ezinneamaka M. Ashibogwu, Chukwuemeka C. Njoku, Chidera M. Ugwuegbu, Bostock C. Okafor, Obinna H. Tony-Okpalaobi, et al.

    Background: Orange juice (OJ) contains ascorbic acid, which has antioxidant properties that would be expected to protect against haemolytic effects and possibly interfere with the antimalarial mechanism of the artemisinin-based combination therapy. This study was designed to investigate the dose and time-dependent effect of OJ on the anti-malarial efficacy of artemether-lumefantrine (AL). Methods: Malaria was induced by inoculating plasmodium berghei parasite through the intraperitoneal route to albino mice. The infection was allowed to establish for 3 days, followed by treatment with AL alone, and its combination with graded doses of OJ. Separate doses of OJ were also administered to different groups. Results: Treatment with AL alone produced total parasite clearance (100%) in days 3 and 4 post-treatment. Co-administration of AL with graded doses of OJ showed significant (p<0.05) increase in parasitemia at OJ combination doses of 10, 8, and 6 ml/kg. Unlike antagonistic combination interaction exhibited by higher combination doses of OJ, lower combination doses of 4 and 2 ml/kg potentiated the antiplasmodial activity of AL. Compared to vehicle (malaria) control group, a significant (p<0.05) increase in PCV was achieved at combination OJ doses of 10, 8, 6, and 4 ml/kg. Combination doses of OJ at 10, 8, 6 ml/kg restored the catalase enzyme activity to the level that exist in uninfected naïve control group. Conclusions: OJ showed both antagonistic and beneficial interactions with AL at higher and lower doses, respectively. Combination of OJ with AL also has a beneficial effect in reducing both parasite and AL-induced oxidative stress.

  • Biomarkers for Tuberculosis Diagnosis and Monitoring: A Review of Translational Progress

    by Olabisi Promise Lawal, Olufemi Adesola Adedayo, Sokoya Itunuoluwa Dorcas, Olukunle O. Akanbi, Bostock Chinecherem Okafor, Ikechukwu Kanu, Precious Esong Sone, John Opeyemi Patrick, Taiwo Oluwole Fabiyi, Bankole Israel Adeyemi, et al.

    Tuberculosis (TB) still presents a major threat to public health, and accurate diagnosis of tuberculosis, monitoring TB treatment, as well as TB drug resistance are still challenging goals. Research in biomarkers—both host, pathogen pathogen-derived—has led to novel frontiers in the diagnosis and management of TB. These advancements contribute to faster diagnosis, customized treatment plans, and better monitoring of response to therapy. Direct pathogen-based markers, such as M. tuberculosis DNA, lipoarabinomannan (LAM), and mycobacterial proteins, that directly demonstrate infection, have the most potential, particularly in resource-poor settings. Cytokines such as interferon-gamma (IFN-γ) and inflammatory markers, such as C-reactive protein (CRP), are endogenous biomarkers that mirror responses of the immune system and may play a role in the management of treatment, especially in immunocompromised populations, such as patients with HIV. These progresses notwithstanding, the application of a biomarker-centered approach on a large scale remains a major obstacle, due to technical, economic, and regulatory constraints. Furthermore, various performances among the biomarkers in different populations limit clinical utility. Future studies in this area should aim to create point-of-care diagnostics, multi-biomarker panels, and to integrate the device with digital health technology platforms for real-time monitoring. These methods have the potential to substantially improve TB control, particularly in low- and middle-income countries. If current challenges can be overcome and research horizons broadened, biomarker-driven diagnosis and monitoring strategies may have key contributions in global TB control.